[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"allergic-rhinitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:allergic-rhinitis":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,42,0,25,[9,48,89,127,158,188,212,249,286,316,344,371,396,418,445,465,493,517,548,572,593,633,652,675,695],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100642439","phase-4-evaluation-of-allergen-specific-vaccination-of-dog-allergic-patients-in-swedish-practice-100642439",false,"NCT07651891","Evaluation of ALLERgen Specific Vaccination of DOG Allergic Patients in Swedish Practice","ALLERDOG","Inclusion Criteria\n\nThe subject has provided written informed consent to participate in the study.\n\n* Age 18-50 years.\n* Moderate-to-severe allergic symptoms upon exposure to dogs.\n* Dog allergy confirmed by positive specific IgE.\n* Considered suitable by the investigator for treatment with Alutard SQ Dog in accordance with the approved Summary of Product Characteristics (SmPC).\n* Female subjects of childbearing potential must use adequate contraception.\n* A negative pregnancy test must be obtained prior to enrolment.\n\nExclusion Criteria\n\n* Pregnancy or breastfeeding.\n* Autoimmune or connective tissue disease.\n* Cardiovascular disease.\n* Hepatic disease.\n* Renal disease.\n* Malignancy.\n* Upper airway disease (e.g., non-allergic sinusitis or nasal polyposis).\n* Chronic obstructive or restrictive lung disease.\n* Treatment with medications that may interfere with the immune response.\n* Previous immunotherapy or chemotherapy.\n* Significant chronic disease.\n* Major metabolic disease.\n* Alcohol or substance abuse.\n* Mental or cognitive incapacity that may impair compliance with study procedures.\n* Known or suspected hypersensitivity to the study product.\n* Suspected or confirmed bacterial infection.\n* Clinically relevant allergy to house dust mite.\n* Current dog ownership.\n* Any condition that, in the investigator's opinion, may make participation, follow-up, or study assessments inappropriate.\n* Any subject considered unsuitable for enrolment according to the principles of the Declaration of Helsinki.","ALL","18 Years","50 Years",{"count":21,"type":22},40,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","STUDY DESIGN A single-center prospective before-and-after study evaluating the effect of Alutard SQ Dog in 40 men and women with moderate-to-severe dog allergy. Participants will serve as their own controls.\n\nSTUDY OUTLINE\n\nThe study will begin in the fall of 2026 and will be conducted over a one-year period. At baseline, participants will be asked to record their allergic symptoms, and assessments of lung function and nasal airflow will be performed. Blood samples will also be collected.\n\nFollowing the baseline assessments, participants will undergo allergen provocation by entering a facility containing dogs. After a 30-minute exposure to dogs, participants will again be asked to record their allergic symptoms and will undergo the same assessments performed at baseline.\n\nAllergen immunotherapy (AIT) with Alutard SQ Dog will then be initiated according to the standard treatment regimen and continued for one year. At the end of the treatment period, the same provocation procedure and assessments will be repeated. Participants will enter a facility containing dogs, followed by symptom recording and evaluation of lung function, nasal airflow, and relevant laboratory parameters.",[28,29],"Allergic Rhinitis","Asthma (Diagnosis)",[31,32,33,34],"AIT","SCIT","Allergic rhinitis","Asthma","RECRUITING","2026-06-24",{"date":38,"type":39},"2026-06-29","ACTUAL",{"date":41,"type":22},"2026-08-01",{"date":43,"type":22},"2027-12-01",{"name":45,"class":46},"Karolinska Institutet","OTHER",2,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":66,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":88},"100637983","observational-study-of-rhinosedal-in-acute-nasal-obstruction-100637983","NCT07620522","Observational Study of RHINOSEDAL in Acute Nasal Obstruction","Prospective Multicenter Before-After Study in Children and Adults Treated for Acute Nasal Obstruction With RHINOSEDAL","RHINOSEDAL","Inclusion Criteria:\n\n* Age 8 years or older.\n* Acute nasal obstruction evolving for less than 48 hours associated with common cold, allergic or non-allergic rhinitis, or rhinosinusitis.\n* Baseline NOSE score \\>40\u002F100.\n* No warning signs such as pus, unilateral obstruction, bleeding, or pain.\n* RHINOSEDAL prescribed by the investigator.\n* Written informed consent signed.\n* Affiliated with a health insurance system.\n\nExclusion Criteria:\n\n* Known anatomical cause of chronic nasal congestion.\n* Corticosteroid use within the previous 2 days.\n* NSAID use within the previous 2 days.\n* Sympathomimetic use within the previous 2 days.\n* Nasal decongestant or nasal irrigation within the previous 2 days.\n* Antihistamines unless stable for more than 48 hours and maintained.\n* Contraindication listed in the RHINOSEDAL instructions for use.\n* Patient under legal protection.\n* Pregnant or breastfeeding women.","8 Years",{"count":58,"type":22},126,"OBSERVATIONAL","This prospective, multicenter, national, observational, non-interventional post-market clinical follow-up study evaluates the performance and safety of RHINOSEDAL in children and adults presenting with acute nasal obstruction associated with common cold, allergic or non-allergic rhinitis, or rhinosinusitis. Patients prescribed RHINOSEDAL in routine care will be followed for 6 ±1 days using patient-reported outcome measures including the NOSE score.",[62,63,28,64,65],"Nasal Obstruction","Common Cold","Non-allergic Rhinitis","Rhinosinusitis",[67,68,69,70,71,72,73,74,75,76],"nasal obstruction","NOSE score","rhinitis","rhinosinusitis","common cold","nasal congestion","saline irrigation","medical device","PMCF","real-world evidence","NOT_YET_RECRUITING","2026-05-27",{"date":80,"type":39},"2026-06-02",{"date":82,"type":22},"2026-10-15",{"date":84,"type":22},"2027-12-31",{"name":86,"class":87},"Laboratoires Elerte","INDUSTRY",1,{"id":90,"slug":91,"hasResults":12,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":96,"sex":17,"minAge":97,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":23,"phases":101,"briefSummary":103,"conditions":104,"keywords":108,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":88},"100609281","emotichealth-promoting-adolescent-health-through-a-serious-game-100609281","NCT07212530","EmoTIChealth: Promoting Adolescent Health Through a Serious Game.","\"Promoting Health in Adolescents With and Without Chronic Diseases Through Emotional Development: Design and Implementation of a Serious Game Technology Platform (EmoTIChealth)\"","Inclusion Criteria:\n\n* Informed consent by parents\u002Fguardians and participants.\n* Aged between 12 and 16 years old\n\nExclusion Criteria:\n\n* No access to internet or new technologies\n* Not a Spanish speaker.",true,"12 Years","16 Years",{"count":100,"type":22},600,[102],"NA","The intervention program targets adolescents between 12 and 16 years of age. The intervention program is designed for adolescents during a critical developmental stage marked by significant life transitions, where building strong personal resources and receiving psychological support is essential to foster socioemotional skills and overall well-being. The serious game aims to promote psycho-emotional health in the general adolescent population, supporting healthy development and preventing future emotional difficulties. At the same time, it incorporates specific modules for adolescents living with chronic conditions such as asthma, food allergy, type 1 diabetes, and allergic rhinitis, who may face additional risks of psychological challenges that can complicate treatment and prognosis. By combining universal health promotion with tailored support, the program addresses both the needs of healthy adolescents and those with chronic illnesses.\n\nThe platform integrates digital and technological tools for dynamic and personalized intervention. Artificial intelligence adapts activities and feedback to each participant's socio-demographic profile and evolving needs, this supports directly in participants' daily lives and natural environments, making the experience more relevant and impactful. The serious game, proven effective in engaging young people, goes beyond traditional psychoeducation by creating an interactive environment where adolescents develop socio-emotional competencies, resilience, and health-related knowledge. Through its six thematic areas, the game promotes overall well-being and healthy habits, while its condition-specific modules provide targeted guidance and coping strategies for asthma, food allergies, type 1 diabetes, and allergic rhinitis.",[105,34,28,106,107],"Type 1 Diabetes","Food Allergy","Adolescent Development",[105,34,28,109,110,111,112,113,114,115,116,117],"Food allergy","Serious Game","Technology platform","Psychological intervention","Adolescence","Quality of life","chronic organic illnesses","Socioemotional Education","Health Promotion","2026-05-12",{"date":120,"type":39},"2026-05-13",{"date":122,"type":39},"2025-12-01",{"date":124,"type":22},"2027-08-30",{"name":126,"class":46},"University of Valencia",{"id":128,"slug":129,"hasResults":12,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":23,"phases":136,"briefSummary":137,"conditions":138,"keywords":139,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":88},"100626444","facilitating-surgical-choice-in-patient-with-chronic-hypertrophic-rhinitis-using-a-patient-decision-aid-100626444","NCT07435714","Facilitating Surgical Choice in Patient With Chronic Hypertrophic Rhinitis Using a Patient Decision Aid","Facilitating Surgical Choice in Patient With Chronic Hypertrophic Rhinitis Using a Patient Decision Aid: A Randomized Control Trial","Inclusion Criteria:\n\n* Diagnosed with chronic hypertrophic rhinitis.\n* Outpatients or inpatients scheduled to undergo surgical intervention.\n* Aged 18 years or older and able to communicate in Chinese.\n\nExclusion Criteria:\n\n* Presence of other structural nasal pathologies (e.g., nasal polyps, tumors).\n* Patients undergoing emergency surgery.\n* Individuals unable to live independently or fully comprehend the questionnaire content.\n* Individuals unable to complete the questionnaires.",{"count":135,"type":22},158,[102],"This study is a prospective randomized controlled trial that aims to enroll 158 patients diagnosed with chronic hypertrophic rhinitis who are candidates for inferior turbinate surgery. Participants will be randomly assigned to either the \"standard group\" or the \"PDA group.\" The standard group will receive conventional shared decision-making (SDM) explanations using verbal and visual aids, while the PDA group will additionally receive a printed patient decision aid (PDA) to assist in evaluating the pros and cons of each surgical option. The study will assess patients' decision certainty and decision regret using the SURE scale and the Decision Regret Scale (DRS), respectively, administered before surgery and one month postoperatively. Surgical satisfaction and outcomes will also be evaluated using pre- and postoperative symptom questionnaires. All data will be collected and analyzed by blinded outcome assessors to ensure objectivity. This study involves no invasive procedures and is classified as a low-risk behavioral study. The primary aim is to optimize clinical decision-making processes for patients with chronic hypertrophic rhinitis considering surgical intervention in the otolaryngology setting.",[28],[140,141,142,143,144,145,146,147,69,148],"hypertrophic rhinitis","shared decision making","patient decision aid","Carbon dioxide laser turbinoplasty","Submucosal resection of the inferior turbinate","Microdebrider-assisted inferior turbinoplasty","Radiofrequency thermal ablation of the inferior turbinate","Potassium Titanyl Phosphate laser turbinoplasty","chronic hypertrophic rhinitis","2026-05-11",{"date":151,"type":39},"2026-05-14",{"date":153,"type":39},"2026-03-01",{"date":155,"type":22},"2027-07-31",{"name":157,"class":46},"Taipei Medical University Shuang Ho Hospital",{"id":159,"slug":160,"hasResults":12,"nctId":161,"briefTitle":162,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":164,"enrollmentInfo":165,"targetDuration":4,"studyType":23,"phases":167,"briefSummary":168,"conditions":169,"keywords":171,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":4},"100639902","evaluation-of-the-efficacy-safety-and-tolerability-of-pl-14-allergy-blocker-compared-to-saline-spray-in-patients-with-seasonal-allergic-rhinitis-100639902","NCT07588672","Evaluation of the Efficacy, Safety, and Tolerability of PL-14 Allergy Blocker Compared to Saline Spray in Patients With Seasonal Allergic Rhinitis","Inclusion Criteria:\n\n1. Clinical history of seasonal AR, as reported by the subject, with symptoms for more than two years and exacerbations during the study season for the relevant seasonal allergen (e.g., tree\u002Fgrass pollen\u002Fragweed).\n2. Positive skin prick test (i.e., wheal ≥3 mm larger than the diluent control with erythema) or positive in vitro tests for specific IgE against allergen(s) relevant to the enrollment period at Baseline or within 12 months before enrollment .\n3. Age ≥ 18 years and ≤ 75 years at Screening.\n4. Active symptoms of seasonal AR with an rTNSS score ≥5 at randomization (based on the average rTNSS score during the Run-in Period and rounded to the nearest whole number).\n5. Willing and able to complete a 7-consecutive-day washout prior to the Baseline\u002FRandomization visit, during which the subject will abstain from:\n\n(1) oral or systemic H1 antihistamines, (2) topical antiallergic treatment, (3) nasal vasoconstrictors (Intermittent use of Astepro Allergy - Antihistamine (azelastine) nasal spray as rescue medication is allowed during the trial).\n\n6\\. Females must be non-pregnant and non-lactating, and at least one of the following must apply: i) not a woman of childbearing potential (WOCBP) (post-menopausal for ≥ 12 months and confirmed through testing of FSH levels ≥ 40 IU\u002FL at Screening Visit); ii) WOCBP using a contraceptive method that is highly effective (a low user-dependency method OR a user-dependent method in combination with barrier method) (plus: negative urine pregnancy test and Screening Visit, within 24 hours before the first dose of study intervention and willing to have additional pregnancy tests as required throughout the study ; iii) WOCBP abstinent from sexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) for 28 days from the start of study intervention.\n\n7\\. Willing and able to attend all trial visits. 8. Able to read and understand study documents and follow instructions from the Investigator and study personnel during visits.\n\n9\\. Signed IRB\u002FEC-approved informed consent form obtained prior to any study-related procedures.\n\nExclusion Criteria:\n\n* 1\\. Presence of active, moderate or severe symptoms of non-allergic rhinitis , acute inflammation of the nose, or paranasal sinusitis at Screening or within the 7 days prior.\n\n  2\\. Positive rapid-result COVID-19 antigen test. 3. Uncontrolled asthma under treatment with any medication other than inhaled short-acting beta-2 agonists, or with known FEV1 \\\u003C 70% within the previous 6 months.\n\n  4\\. Diagnosis or symptoms of acute respiratory infection at Screening or within the previous 4 weeks.\n\n  5\\. Vaccinations: i) live vaccine(s) within 1 month prior to Screening or planned during the study; ii) killed vaccine within 1 week prior to Screening; iii) planned COVID-19 vaccine from Day -7 through Day 14.\n\n  6\\. Nasal or paranasal sinus surgery within the previous 8 weeks. 7. Long-term continuous use of inhaled or intranasal glucocorticosteroids (intermittent use is allowed).\n\n  8\\. Initiation of allergen immunotherapy within 3 months prior to Screening, or failure to have reached the maintenance phase of allergen immunotherapy at the time of enrollment, or any change in allergen immunotherapy dose or regimen within 1 month prior to Screening.\n\n  9\\. Treatment with leukotriene receptor antagonists (at Screening or within 1 week prior) or regular\u002Fchronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) at screening or within 1 week prior. Intermittent NSAID use as relief\u002Frescue medication is allowed.\n\n  10\\. Known hypersensitivity to any constituent of the study devices (test \\& control) .\n\n  11\\. Clinically significant nasal abnormalities that may interfere with proper device administration or affect nasal airflow, including but not limited to:\n  * Nasal septal deviation associated with clinically significant nasal obstruction, as determined by the investigator based on physical examination, and resulting in functional impairment (e.g., patient-reported difficulty in airflow).\n  * Nasal polyps\n  * Chronic rhinosinusitis (with or without nasal polyposis)\n  * Turbinate hypertrophy of clinical significance\n  * History of nasal surgery within the past 6 months\n  * Structural abnormalities (e.g., perforated septum, severe nasal valve collapse)\n  * Active nasal infection or acute sinusitis Subjects presenting with any of these conditions will be excluded from participation.\n\n    12\\. Any clinically relevant autoimmune, respiratory (especially with reduction of respiratory capacity) or cardiovascular disease, malignant tumors, bleeding disorders, autoimmune diseases, neurological disorders, or any other abnormality that, in the opinion of the Investigator, may pose a safety risk, confound the clinical performance or safety assessment, or interfere with study participation.\n\n    13\\. Concurrent participation in another clinical study or participation in another clinical study within 30 days prior to Screening.\n\n    14\\. A history of alcohol or drug abuse, within 2 years prior to screening, or current use of recreational drugs (particularly intranasal).\n\n    15\\. Planned travel to a region outside the designated pollen area for the Clinical Research Unit (CRU), as defined in the informed consent form, for ≥24 hours during the 7-day Run-in Period, OR for ≥2 consecutive days or a total of ≥3 days between the randomization visit and the follow-up phone call","75 Years",{"count":166,"type":22},120,[102],"This study is designed to evaluate the efficacy, safety, and tolerability of PL-14 Allergy Blocker compared to saline spray in adults with Seasonal Allergic Rhinitis (SAR).\n\nPL-14 Allergy Blocker is a non-pharmacological, drug-free intranasal mucoadhesive hydrogel designed to form a mechanical barrier on the nasal mucosa and reduce contact between airborne allergens and the nasal lining.\n\nThis is a prospective, randomized, single-blind, multi-center clinical investigation in up to 120 participants at up to 8 sites in the United States. Eligible participants with a history of seasonal allergic rhinitis will be randomized in a 1:1 ratio to receive either PL-14 Allergy Blocker or Ayr® Saline Nasal Mist for up to 30 days.\n\nThe study will evaluate the effect of PL-14 Allergy Blocker on nasal allergy symptoms, quality of life, rescue medication use, and symptom-free days. Safety and local tolerability assessments will also be performed throughout this study period.",[170,28],"Seasonal Allergic Rhinitis (SAR)",[172,173,174,28,175,176,177,178],"PL-14","Allergy Blocker","Seasonal Allergic Rhinitis","Nasal Spray","Pollen Allergy","TNSS","RQLQ","2026-05-09",{"date":181,"type":39},"2026-05-15",{"date":183,"type":22},"2026-07-15",{"date":185,"type":22},"2027-09-30",{"name":187,"class":87},"Polyrizon Ltd.",{"id":189,"slug":190,"hasResults":12,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":12,"sex":17,"minAge":195,"maxAge":97,"enrollmentInfo":196,"targetDuration":4,"studyType":23,"phases":198,"briefSummary":199,"conditions":200,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":88},"100633482","effects-of-adenoidectomy-on-symptoms-and-ige-levels-in-children-with-ar-100633482","NCT07527260","Effects of Adenoidectomy on Symptoms and IgE Levels in Children With AR","Effects of Adenoidectomy With or Without Tonsillectomy on Symptoms and Local IgE Levels in Children With Allergic Rhinitis","Inclusion Criteria:\n\n\\- 3-12 years\n\n1. Children with physician-diagnosed allergic rhinitis and typical symptoms (nasal obstruction, watery rhinorrhea, paroxysmal sneezing);\n2. Co-existing adenoidal and tonsillar hypertrophy meeting surgical indications;\n3. No systemic or topical corticosteroids, leukotriene antagonists, or antihistamines within the past 3 months.\n\nExclusion Criteria:\n\n1. Prior adenoidectomy, tonsillectomy, or radio-frequency ablation;\n2. Nasal polyps, cystic fibrosis, primary ciliary dyskinesia, fungal rhinosinusitis, systemic vasculitis\u002Fgranulomatosis, tumor, or immunodeficiency;\n3. Endoscopic nasal surgery within 6 months or severe asthma precluding surgery;\n4. Upper respiratory infection within 4 weeks;\n5. Serious metabolic, cardiovascular, immune, neurologic, hematologic, gastrointestinal, cerebrovascular, or respiratory disease, or any condition judged by the investigator to interfere with outcome assessment or participant safety;\n6. Currently enrolled or within 30 days of participation in another clinical trial.","3 Years",{"count":197,"type":22},36,[102],"This study aims to evaluate the effects of conservative management versus surgical intervention (adenoidectomy alone or adenotonsillectomy) on symptoms and local IgE levels in children with allergic rhinitis (AR) accompanied with adenotonsillar hypertrophy. The primary objectives include the impact of conservative management and surgical interventions on AR symptoms and local IgE levels. The second outcomes include serum IgE levels, inflammatory cell profiles within the nasal mucosa, and postoperative complications.",[201,202,28],"Adenoidectomy","Tonsillectomy","2026-04-13",{"date":205,"type":39},"2026-04-14",{"date":207,"type":22},"2026-04-11",{"date":209,"type":22},"2027-04-01",{"name":211,"class":46},"Tongji Hospital",{"id":213,"slug":214,"hasResults":12,"nctId":215,"briefTitle":216,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":12,"sex":17,"minAge":218,"maxAge":219,"enrollmentInfo":220,"targetDuration":4,"studyType":23,"phases":222,"briefSummary":223,"conditions":224,"keywords":228,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":247,"locationsCount":88},"100558150","dietary-intervention-on-atopy-100558150","NCT06547372","Dietary Intervention on Atopy","Inclusion Criteria:\n\n1. Presence of current, mild-to-moderate atopic dermatitis\u002Feczema at flexural areas\n2. 21 to 65 years of age (inclusive) at screening\n3. Must be English-literate and able to give informed consent in English\n4. Be residing in Singapore and will not be travelling outside of Singapore during the study period\n5. Reliable and willing to follow study procedures and be available for the duration of the study\n6. Non-smokers (tobacco and e-cigarette)\n7. Non-drinker (no regular or frequent consumption of alcohol)\n8. Overtly healthy with no pre-existing medical conditions (e.g., diabetes, hypertension, cancer, blood disorders, degenerative\u002Fliver\u002Fautoimmune\u002Fimmune\u002Frenal diseases, or psychiatric conditions)\n9. No food allergies to test foods\n10. No needle phobia\n11. Be willing to follow the instruction provided by the investigators on the use of any moisturiser, cosmetics, and\u002For topical cream on the skin throughout the entire duration of the study.\n\nExclusion Criteria:\n\n1. Concurrent participation in other research studies\n2. Pregnancy or lactating individuals\n3. Known or ongoing psychiatric disorders within 3 years\n4. Known severe nutritional deficiency\n5. Vegetarian\u002Fvegans (as meat will be included in the diet)\n6. Individuals who made a significant dietary change in the past 12 months\n7. Having a pre-existing dietary restriction that would interfere with the adherence to a whole diet meal\n8. Regular use of strong medication (western and\u002For traditional), therapies, and alternative medications\n9. Regular nutritional supplements in the past 12 months Regular consumption of oral contraceptive pills and\u002For steroid hormones\n10. Antibiotic use in the past 2 months\n11. Any long-term hospitalisation or surgery during the 6 months before enrolment in study\n12. Significant change in weight (+\u002F- 5.0%) during the past month\n13. History of bleeding diathesis or coagulopathy (or any bleeding disorders)\n14. Having donated blood of more than 500 mL within 4 weeks of study enrolment","21 Years","65 Years",{"count":221,"type":22},110,[102],"Diet is a key determinant of overall health, with growing evidence associating dietary patterns with allergic diseases. Among these, atopic dermatitis (AD) is of particular interest as it often represents the earliest manifestation of the atopic triad. Investigating dietary interventions in AD therefore provides a relevant model to better understand how diet may influence the onset and progression of allergic disease more broadly.",[225,226,227,28],"Atopic Dermatitis","Atopic","Allergic Diseases",[229,230,231,232,233,234,235,236,237,238,239,240],"Atopic dermatitis","My Healthy Eating Plate","eczema","healthy diet","diet","meals","foods","allergic","allergy","atopic","Singapore","nutrients","2026-03-26",{"date":243,"type":39},"2026-04-01",{"date":245,"type":39},"2024-05-10",{"date":84,"type":22},{"name":248,"class":46},"National University of Singapore",{"id":250,"slug":251,"hasResults":12,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":255,"eligibilityCriteria":256,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":257,"targetDuration":4,"studyType":23,"phases":259,"briefSummary":260,"conditions":261,"keywords":262,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":88},"100625176","evaluation-of-a-digital-tool-to-improve-aeroallergen-immunotherapy-adherence-navigaitme-project-100625176","NCT07419230","Evaluation of a Digital Tool to Improve Aeroallergen Immunotherapy Adherence. NavigAITme Project","Pragmatic Randomized Prospective Clinical Study to Evaluate the Effectiveness of a Digital Application to Improve Aeroallergen Immunotherapy Adherence in Real Life. The NavigAITme Project","NavigAIT","Inclusion Criteria:\n\n* Patients of any age and sex\n* Patients who have received their first prescription for a new aeroallergen immunotherapy treatment as part of their routine care for allergic rhinitis with or without asthma\n* Patients who have been prescribed only a single immunotherapy product\n* Patients who have been prescribed a commercially available product, from any company, for sublingual or subcutaneous administration\n* Patients who have provided the first photograph of the product for which they are entering the study\n\nExclusion Criteria:\n\n* Patients receiving AIT prescription for asthma only, and do not suffer allergic rhinitis\n* Administration routes other than subcutaneous or sublingual\n* Patients receiving AIT prescription for other indications, e.g., food or hymenoptera allergies\n* Patients who have received immunotherapy in the last 3 years or are currently undergoing treatment with an AIT product other than the one being studied in the current project.\n* Patients who have received prescription for two or more different immunotherapy products simultaneously",{"count":258,"type":22},880,[102],"Aaeroallergen Immunotherapy (AIT) is indicated in the treatment of allergic rhinitis and asthma, and has shown efficacy to control symptoms and induce immunomodulatory changes that support post discontinuation efficacy. Data from clinical trials provides founding for its efficacy and safety profile, but the therapy needs to be withheld for a minimum of 3 years, with modalities that imply daily or near daily administration of a sublingual extract, or subcutaneous injections, every 4 to 6 weeks. This treatment regimen often faces other limitations such as cost, patient´s lack of knowledge regarding efficacy\u002Fsafety, or potentiality of adverse reactions. These factors have been pointed out as main reasons for a reported low level of treatment adherence in real life.\n\nWhile overall literature data on treatment adherence ranges widely, from 6% to 93% of patients finalising the minimum of 3 years, current data from precise German registries inform of persistence at 3 years being very low, varying from 5.2% to 18.2% with differences depending on extract, route and patient´s age.\n\nSurprisingly, even if the Scientific community acknowledges patient adherence as a very relevant weak point, there´s paucity of structured strategies to tackle this issue, and those available, have mostly been developed in single centers, for periods below the 3 years of AIT recommended duration. In the era of technology, and with the spreading of mobile applications (App), new approaches are currently ongoing to counteract this important drawback . In this landscape, this study aims at creating a new App that will be thoroughly tested in a prospective long-term randomized trial, to improve AIT persistence.",[28],[263,264,33,265,266,267,31,268,269,270,271,272,273,274,275,276,32],"allergen immunotherapy","Respiratory allergy","Adherence","Implementation","Persistance","Mobile App","Real life study","mites","grass","pollen","animal dander","sublingual","subcutaneous","SLIT","2026-03-18",{"date":279,"type":39},"2026-03-23",{"date":281,"type":39},"2026-03-11",{"date":283,"type":22},"2030-03-11",{"name":285,"class":46},"Fundación de Investigación Biomédica - Hospital Universitario de La Princesa",{"id":287,"slug":288,"hasResults":12,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":4,"eligibilityCriteria":292,"healthyVolunteers":12,"sex":17,"minAge":293,"maxAge":294,"enrollmentInfo":295,"targetDuration":4,"studyType":23,"phases":297,"briefSummary":298,"conditions":299,"keywords":302,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":88},"100627821","effect-of-aiartificial-intelligence-based-storytelling-video-on-anxiety-and-fear-during-skin-prick-test-in-children-100627821","NCT07453615","Effect of AI(Artificial Intelligence)-Based Storytelling Video on Anxiety and Fear During Skin Prick Test in Children","AI-Based Video-Mediated Cognitive Preparation in Skin Prick Testing: A Prospective, Randomized Controlled Trial","Inclusion Criteria:\n\n* Children aged between 4 and 10 years (from 4th birthday to 11th birthday).\n* Children undergoing a Skin Prick Test (SPT) for the first time.\n* Presence of suspected Allergic Rhinitis and\u002For Asthma.\n* Cognitive ability to understand Turkish, follow the video story, and interpret visual assessment scales.\n* Parents with internet access to view the digital content.\n* Obtained parental informed consent and child assent (for ages 7 and above)\n\nExclusion Criteria:\n\n* Previous experience with Skin Prick Testing or a history of frequent medical procedures (e.g., frequent blood draws, surgeries) due to chronic illness.\n* Diagnosed with Autism Spectrum Disorder, severe ADHD(attention deficit hyperactivity disorder), intellectual disability, or severe psychiatric conditions preventing cooperation.\n* Significant visual or hearing impairments that prevent engagement with the video content.\n* Use of anxiolytics, sedatives, or medications affecting cognitive functions within the last 24 hours.\n* Chronic health problems (e.g., malignancy, immunodeficiency) that may elevate baseline anxiety levels.\n* Patients undergoing SPT for suspected Food Allergy, Drug Allergy, or Bee Venom Allergy.\n* For the intervention group: Failure to watch the video or answering the three \"validation questions\" incorrectly on the procedure day.","4 Years","10 Years",{"count":296,"type":22},100,[102],"This study evaluates the effectiveness of an AI-generated therapeutic storytelling video on pre-procedural anxiety and fear levels in children aged 4 to 10 years undergoing their first Skin Prick Test (SPT). The study aims to determine if watching a cognitive preparation video at home prior to the appointment reduces anxiety compared to standard care. Participants will be randomized into two groups: an intervention group watching the AI-generated video and a control group receiving standard clinic care",[300,301,28,29],"Anxiety","Fear Anxiety",[303,304,305,306],"Skin Prick Test","Artificial Intelligence","Cognitive Preparation","Storytelling","2026-03-16",{"date":277,"type":39},{"date":310,"type":39},"2026-03-15",{"date":312,"type":22},"2026-09-15",{"name":314,"class":315},"Antalya Training and Research Hospital","OTHER_GOV",{"id":317,"slug":318,"hasResults":12,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":4,"eligibilityCriteria":322,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":219,"enrollmentInfo":323,"targetDuration":4,"studyType":23,"phases":324,"briefSummary":327,"conditions":328,"keywords":330,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":88},"100589897","phase-1-safety-and-immunogenicity-of-cat-allergen-intralymphatic-immunotherapy-in-patients-with-cat-allergy-with-and-without-asthma-100589897","NCT06960382","Safety and Immunogenicity of Cat-allergen Intralymphatic Immunotherapy in Patients With Cat Allergy With and Without Asthma","Safety and Immunogenicity of Cat-allergen Intralymphatic Immunotherapy: an Open Label Phase II Study in Patients With Cat Allergy With and Without Asthma","Inclusion Criteria:\n\n* Informed consent as documented by signature.\n* Cat-dander-induced ARC as confirmed by patient history and type-1-sensitization to cat dander in skin and\u002For serum.\n\nExclusion Criteria:\n\n* Hypersensitivity to phenol.\n* Planned depot steroid injection for treatment of ARC\n* Patients with uncontrolled asthma or FEV1 \\\u003C 70% of the predicted value in adults (after adequate pharmacological therapy).\n* Patients with a severe asthma exacerbation in the past 3 months.\n* Irreversible secondary changes in the affected organ (e.g., emphysema, bronchiectasis).\n* Chronic obstructive or restrictive lung disease.\n* Patients with active systemic autoimmune diseases and patients with immune deficiencies or immune weaknesses.\n* Severe chronic inflammatory diseases.\n* Concomitant infection with fever or other signs\u002Fsymptoms of an acute or chronic infection at treatment visit.\n* Chronic obstructive or restrictive lung disease\n* Patients with malignant tumours that currently have clinical significance.\n* Disease or conditions rendering the treatment of anaphylactic reactions difficult (symptomatic coronary heart diseases, severe arterial hypertension, and treatment with beta-blockers).\n* Known cardiovascular disease, i.e., not even NYHA class I.\n* Use of ACE-blockers.\n* Recent or on-going hepatic or renal disease.\n* Severe chronic renal insufficiency (due to aluminium burden).\n* Alcohol or drug abuse\n* Women who are pregnant and breast feeding\n* Women of childbearing age who wish to become pregnant or do not use contraception.\n* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant.\n* Participation in another study with investigational drug within the 30 days preceding and during the present study.",{"count":197,"type":22},[325,326],"PHASE1","PHASE2","The goal of this clinical trial is to evaluate the safety and tolerability of intralymphatic immunotherapy (ILIT) with ALUTARD SQ Felis domesticus in patients with cat allergy-induced allergic rhinitis and asthma. The main questions it aims to answer are:\n\nIs ILIT with ALUTARD SQ Felis domesticus safe and well tolerated?\n\nWhat immunological responses play a role in ILIT?\n\nResearchers will compare the effects of ILIT to existing subcutaneous immunotherapy (SCIT) approaches to assess safety, tolerability, immunogenicity, and efficacy.\n\nParticipants will:\n\nReceive 3-4 ILIT injections of ALUTARD SQ Felis domesticus into an inguinal lymph node, guided by ultrasound.\n\nUndergo safety monitoring, including WAO guidelines for systemic allergic reactions and tryptase measurement.\n\nComplete lung function tests, questionnaires, and a modified nasal provocation test to evaluate asthma effects and treatment efficacy.\n\nProvide blood samples for ImmunoCAP and basophil activation testing using CAST ELISA.\n\nInclusion criteria: Adults aged 18-65 with cat-dander-induced allergic rhinitis and asthma.\n\nExclusion criteria: Hypersensitivity to treatment components, systemic steroid use, uncontrolled asthma (FEV1 \\\u003C 70%), recent severe asthma exacerbations, or serious comorbidities.\n\nThe study aims to generate data to inform future efficacy trials.",[28,329],"Allergic Asthma",[331,332,69,333,334,335],"cat allergy","asthma","immunotherapy","intralymphatic injection","ILIT","2026-03-12",{"date":307,"type":39},{"date":339,"type":39},"2025-08-20",{"date":341,"type":22},"2028-03-31",{"name":343,"class":46},"University of Zurich",{"id":345,"slug":346,"hasResults":12,"nctId":347,"briefTitle":348,"officialTitle":349,"acronym":4,"eligibilityCriteria":350,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":351,"enrollmentInfo":352,"targetDuration":4,"studyType":23,"phases":354,"briefSummary":355,"conditions":356,"keywords":357,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":370},"100627833","safety-and-efficacy-of-small-extracellular-vesicles-nebulizer-in-patients-with-allergic-rhinitis-complicated-with-asthma-100627833","NCT07453771","Safety and Efficacy of Small Extracellular Vesicles Nebulizer in Patients With Allergic Rhinitis Complicated With Asthma","Safety and Preliminary Efficacy of Small Extracellular Vesicles (Code: hUC-MSC-sEV-002) Nebulizer in Patients With Allergic Rhinitis Complicated With Asthma: A Multicenter, Prospective, Randomized, Double-Blind Phase I\u002FII Clinical Study","Inclusion Criteria:\n\n1. Aged 18-60 years, regardless of gender;\n2. Patients with moderate to severe allergic rhinitis (with sleep\u002Fwork\u002Fstudy\u002Fdaily activity impairment or distressing symptoms) meeting the diagnostic criteria of the international Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines, positive for at least one inhalant allergen skin prick test, and concurrent asthma complying with the Global Initiative for Asthma (GINA) 2022 guidelines;\n3. Suboptimal response to antiallergic medication treatment for one year prior to enrollment;\n4. Patients who decline allergen-specific immunotherapy, or have no available specific therapy for the relevant allergen, or failed allergen-specific immunotherapy;\n5. Females of childbearing potential must agree to avoid pregnancy during study participation and for 30 days after the final visit;\n6. Subjects or their legal representatives must be able to sign the informed consent form and comply with the study requirements for medication administration and follow-up.\n\nExclusion Criteria:\n\n1. Complicated with other nasal and sinus diseases that may affect the reasonable assessment of efficacy and\u002For safety;\n2. Suffering from uncontrolled asthma or poorly controlled asthma symptoms;\n3. Suffering from malignant tumors, severe immune diseases, long-term use of immunosuppressants, or immunodeficiency;\n4. Having unstable conditions due to respiratory tract infection and\u002For acute asthma exacerbation within 4 weeks prior to the initial screening visit;\n5. Currently receiving treatment with beta-blockers or angiotensin-converting enzyme (ACE) inhibitors;\n6. Suffering from mental illnesses;\n7. Suffering from severe systemic diseases, such as cases of peptic ulcers, diabetes mellitus, and heart failure;\n8. Specific infections such as syphilis, leprosy, and tuberculosis;\n9. Females who are currently pregnant, planning to become pregnant soon, or breastfeeding;\n10. Patients who are currently participating in other clinical trials or have participated in other clinical trials within 30 days prior to the initial screening visit;\n11. Patients who are currently receiving allergen desensitization therapy or biologic therapy;\n12. Positive for hepatitis B surface antigen, hepatitis C virus antibody, syphilis serological antibody, or human immunodeficiency virus (HIV) antibody;\n13. In addition to the above conditions, patients will be excluded if the investigators consider them unsuitable for participation in this clinical study for other reasons.","60 Years",{"count":353,"type":22},18,[102],"This trial aims to evaluate the safety, tolerability and efficacy of hUC-MSC-sEV-002 nebulizer in patients with allergic rhinitis and asthma. It consists of two parts: ① Single-center dose exploration (The Affiliated Hospital of Qingdao University): A 3+3 escalation design will test three doses (1×10⁸, 1×10⁹, 1×10¹⁰ particles\u002FmL) to determine the maximum tolerated dose (MTD).Three subjects will be enrolled in each dose group. If no Dose-Limiting Toxicity (DLT) is observed among the 3 subjects, the study may proceed to the next dose exploration. If 1 out of the 3 subjects experiences DLT, an additional 3 subjects will be enrolled in the same dose group; the study may move to the next dose exploration only if no DLT is observed in these additional 3 subjects. If more than 1 out of the 3 subjects develops DLT, the previous dose group will be defined as the MTD. A total of at least 9 and at most 18 subjects will be recruited for this clinical trial. ② Multi-center case expansion: Participants will be randomized 2:1 to hUC-MSC-sEV-002 or placebo groups for efficacy comparison.Eligibility criteria: 18-60 years old; moderate-to-severe allergic rhinitis (ARIA guidelines) with positive inhaled allergen skin test; asthma diagnosed per GINA 2022; signed informed consent.Intervention: Nebulization once daily (5 times\u002Fweek, 2 weeks, 10 doses total). Follow-up visits at baseline, Week 2, 4, 12, 24, including symptom scales, lung function tests, nasal endoscopy, nasal exhaled nitric oxide test, chest X-ray, blood tests, and electrocardiogram. The trial is approved by the Medical Ethics Committee of The Affiliated Hospital of Qingdao University (No. QYFYEC2025-192). Participants may withdraw anytime without affecting medical care. Study period: Aug 2025-Aug 2027. Sample size: 9-18 for Part 1; Part 2 size based on Part 1 results.",[28,34],[358,359,33,34,360],"Small extracellular vesicles","Nebulizer formulation","Randomized, double-blind","2026-02-27",{"date":363,"type":39},"2026-03-06",{"date":365,"type":22},"2026-03-05",{"date":367,"type":22},"2027-08-31",{"name":369,"class":46},"The Affiliated Hospital of Qingdao University",5,{"id":372,"slug":373,"hasResults":12,"nctId":374,"briefTitle":375,"officialTitle":375,"acronym":376,"eligibilityCriteria":377,"healthyVolunteers":12,"sex":17,"minAge":378,"maxAge":379,"enrollmentInfo":380,"targetDuration":4,"studyType":23,"phases":382,"briefSummary":383,"conditions":384,"keywords":385,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":387,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":395},"100291602","validation-of-an-allergic-rhinitis-control-test-in-children-100291602","NCT03075917","Validation of an Allergic Rhinitis Control Test in Children","ARCTEnfants","Inclusion Criteria:\n\n* Patients aged 5 to 11 years old, consulting a practitioner for an allergic rhinitis\n* Parents formulated their study participation agreement by signing the consent form.\n\nExclusion Criteria:\n\n* Patients that are already treated for the actual episode of allergic rhinitis and are satisfied of the treatment.","5 Years","11 Years",{"count":381,"type":22},135,[102],"Allergic rhinitis is a common condition that affects adults as well as children and adolescents, often with impaired quality of life. Patients often report a poor level of satisfaction with the effectiveness of their treatment and are always looking for more drug combinations to improve their symptom. Several tools exist for assessing control of allergic rhinitis, but none has been validated in teenagers or in children. A study conducted in 2008, resulted in the validation of a self-administered control test of allergic rhinitis (ARCT) in patients from 12 years of age. We propose to adapt ARCT adult to pediatric population from 5 to 11 years old.",[28],[33],"2025-12-31",{"date":388,"type":39},"2026-01-05",{"date":390,"type":39},"2017-05-04",{"date":392,"type":22},"2027-07",{"name":394,"class":46},"University Hospital, Montpellier",6,{"id":397,"slug":398,"hasResults":12,"nctId":399,"briefTitle":400,"officialTitle":400,"acronym":401,"eligibilityCriteria":402,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":403,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":405,"conditions":406,"keywords":407,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":416,"locationsCount":88},"100617232","implementation-of-an-allergic-rhinitis-severity-questionnaire-in-ent-consultations-100617232","NCT07315945","Implementation of an Allergic Rhinitis Severity Questionnaire in ENT Consultations","QSRA-ORL","Inclusion Criteria:\n\n* Adult (≥18 years)\n* Follow-up at the ENT department of Hautepierre University Hospital for allergic rhinitis\n\nExclusion Criteria:\n\n* Asymptomatic individuals not requiring follow-up consultations.",{"count":404,"type":22},30,"Allergic rhinitis is a very common condition (affecting 1 in 5 people in Europe) and a costly one for society (direct and indirect costs). Symptoms vary depending on the time of year, and treatments are primarily symptomatic, with follow-up in ENT consultations. Scientific societies (EAACI, FDA, EMA) recommend using a universal tool (severity score) (the CSMS score, SCST in French) to monitor severity and follow-up, and to obtain consistent data that can be extrapolated to other scientific data (meta-analyses).\n\nTherefore, investigators in the ENT department use this SCST score (as well as others such as the SNOT 22 score) to assess the severity of allergic rhinitis in our patients and its progression.\n\nTbe investigators wish to confirm the acceptability of this tool for patients, and the statistical value of its properties.",[28],[28,408,409],"SCST score","SNOT 22 score","2025-12-18",{"date":388,"type":39},{"date":413,"type":39},"2025-06-10",{"date":415,"type":22},"2026-02",{"name":417,"class":46},"University Hospital, Strasbourg, France",{"id":419,"slug":420,"hasResults":12,"nctId":421,"briefTitle":422,"officialTitle":423,"acronym":424,"eligibilityCriteria":425,"healthyVolunteers":12,"sex":17,"minAge":97,"maxAge":4,"enrollmentInfo":426,"targetDuration":428,"studyType":59,"phases":4,"briefSummary":429,"conditions":430,"keywords":431,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":437,"startDateStruct":439,"completionDateStruct":441,"leadSponsor":443,"locationsCount":4},"100601170","climair-ai-to-assess-the-impact-of-pollution-and-climate-on-respiratory-health-in-europe-100601170","NCT07107009","ClimAIr: AI to Assess the Impact of Pollution and Climate on Respiratory Health in Europe","Climate Change and Air Contamination: Artificial Intelligence Applied on the Correlation Between Air Pollutants and Non-communicable Respiratory Diseases in Europe (ClimAIr)","ClimAIr","Inclusion Criteria:\n\n1. Patients with health insurance based in Malaga, Milan, Luxembourg, Thessalonikki, Lodz, Berlin, Toulousse, Chervnivtsi and Brasov (the places where environmental\u002Fclimate information will be obtained from, only one recruitment place for partner).\n2. 3-year history of chronic rhinitis symptoms during the corresponding pollen season, while residing in the same household AND attending the same school\u002Fcollege or holding the same job position.\n3. Positive SPT and serum allergen-specific IgE \\>0.35 kUA\u002FL. The pollen species driving the nasal symptoms will be Olea europaea, Phleum pratense or Betula pendula.\n4. Patients can be sensitized to other aeroallergens if the nasal symptoms occur exclusively or aggravate unequivocally during the pollen season of the three allergens of interest.\n\nExclusion Criteria:\n\nLack of reliable information in e-health records, allergen immunotherapy (any allergen) during the previous 5 years, systemic immunosuppressants or biologicals in the previous six months, chronic rhinosinusitis, and severe systemic conditions.",{"count":427,"type":22},1906,"3 Months","The ClimAIr project will expand the evidence-based understanding of climate change, air pollution, and non-communicable respiratory diseases by using Artificial Intelligence (AI) tools. It will gather data on greenhouse gases levels and disaster risks, information on serious air pollutants and respiratory diseases' prevalence. The AI powered tools will be employed to generate better intervention methods and improve public health outcomes.\n\nFederated Learning (FL) will be used to develop AI models to protect patients' privacy. By raising public awareness and delivering the ClimAIr tool - specifically designed to health workers, urban planners and policy makers - the project aims to influence policy decisions, promote healthier environments, and reduce respiratory diseases in Europe, which will be tested and validated the ClimAIr tool in specific municipalities that are part of the project. ClimAIr draws on a consortium of 21 partners from 15 European countries, including carefully selected health centres across Europe - in Spain, Luxembourg, Ukraine, Italy, France, Germany, Greece, Romania and Poland - focused on respiratory diseases, which will provide disease data and explore metabolic routes of the studied contaminants\u002Fdiseases. ClimAIr is composed of an interdisciplinary team formed by research centres, ethical AI and modelling experts, SSH specialists, municipal governance, and a Communication \\& Dissemination (C\\&D) expert team dedicated to achieving and spread the results of the project.",[28,34],[432,433,434,435,424],"Air contamination","Air pollutants","Non-communicable respiratory diseases","Climate change","2025-12-09",{"date":438,"type":39},"2025-12-17",{"date":440,"type":22},"2026-01",{"date":442,"type":22},"2027-12",{"name":444,"class":46},"Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud",{"id":446,"slug":447,"hasResults":12,"nctId":448,"briefTitle":449,"officialTitle":449,"acronym":4,"eligibilityCriteria":450,"healthyVolunteers":12,"sex":17,"minAge":97,"maxAge":164,"enrollmentInfo":451,"targetDuration":4,"studyType":23,"phases":453,"briefSummary":454,"conditions":455,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":457,"startDateStruct":459,"completionDateStruct":461,"leadSponsor":463,"locationsCount":4},"100615570","phase-4-a-prospective-randomized-controlled-study-comparing-the-efficacy-of-intranasal-corticosteroids-incs-combined-with-intranasal-antihistamines-inah-and-incs-combined-with-oral-antihistamines-oah-in-the-treatment-of-moderate-to-severe-allergic-rhinitis-symptoms-100615570","NCT07294326","A Prospective, Randomized, Controlled Study Comparing the Efficacy of Intranasal Corticosteroids (INCS) Combined With Intranasal Antihistamines (INAH) and INCS Combined With Oral Antihistamines (OAH) in the Treatment of Moderate to Severe Allergic Rhinitis Symptoms","Inclusion Criteria:\n\n1. Age range: 12-75 years old, both male and female are welcome;\n2. The diagnostic criteria for moderate to severe allergic rhinitis refer to the \"Chinese Guidelines for Diagnosis and Treatment of Allergic Rhinitis (2022, revised edition)\", which states: (1) Symptoms: the presence of 2 or more symptoms such as paroxysmal sneezing, watery nasal discharge, nasal itching, and nasal congestion, with symptoms lasting or accumulating for more than 1 hour per day, with symptoms appearing for at least 1 year, a single symptom score (TNSS score standard) of 2 points or more, and a total nasal symptom score (TNSS score standard) of 6 points or more. May be accompanied by eye symptoms, including itching, tearing, redness, and burning sensation. (2) Signs: Pale and edematous nasal mucosa, accompanied by watery nasal secretions (3) Allergen testing: at least one allergen SPT and\u002For serum specific IgE positive, or nasal provocation test positive. (4) Severe or severe symptoms that have a significant impact on quality of life, including (i) sleep disorders, (ii) disruptions to daily activities, leisure, and\u002For exercise, (iii) disruptions to learning or work, (iv) anxiety, depression, or restlessness;\n3. The enrolled patients reside in Northeast China and meet the follow-up requirements, including Hulunbuir City, Xing'an League, Tongliao City, Chifeng City, and Xilingol League in Heilongjiang Province, Jilin Province, Liaoning Province, and Inner Mongolia Autonomous Region;\n4. The subjects voluntarily participated in this study and signed a written informed consent form.\n\nExclusion Criteria:\n\n1. Patients who are allergic to other excipients such as azelastine hydrochloride, fluticasone propionate, or related drugs;\n2. Pregnant women;\n3. Patients with arrhythmia, severe organic heart disease, glaucoma, prostate enlargement, active tuberculosis, malignant tumors, systemic immune diseases, or uncontrolled active infections, such as acute upper respiratory tract infections, who cannot be treated with relevant drugs;\n4. Other patients who are unwilling to cooperate with treatment or unable to cooperate with follow-up due to serious systemic or mental illnesses;\n5. There are certain organic diseases of the nasal cavity, such as benign and malignant tumors of the nasal cavity, chronic sinusitis with nasal polyps, etc;\n6. Age\\\u003C12 years old or\\>75 years old;\n7. Patients who have received allergen specific immunotherapy or biologic therapy within the past 6 months;\n8. Those who cannot tolerate serious systemic or local adverse reactions during relevant examinations or specimen collection;\n9. Researchers believe that patients who cannot be included in the group.",{"count":452,"type":22},50,[25],"Through prospective exploration of the efficacy of intranasal corticosteroids (INCS) combined with intranasal antihistamines (INAH) and INCS combined with oral antihistamines (OAH) in treating moderate to severe allergic rhinitis symptoms, this study aims to provide evidence-based medical evidence for the standardized treatment of patients with moderate to severe allergic rhinitis accompanied by typical nasal and ocular symptoms.",[28],"2025-12-07",{"date":458,"type":39},"2025-12-19",{"date":460,"type":22},"2026-01-01",{"date":462,"type":22},"2026-11-01",{"name":464,"class":46},"China-Japan Union Hospital",{"id":466,"slug":467,"hasResults":12,"nctId":468,"briefTitle":469,"officialTitle":470,"acronym":471,"eligibilityCriteria":472,"healthyVolunteers":12,"sex":17,"minAge":473,"maxAge":4,"enrollmentInfo":474,"targetDuration":4,"studyType":23,"phases":476,"briefSummary":477,"conditions":478,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":484,"startDateStruct":486,"completionDateStruct":488,"leadSponsor":490,"locationsCount":492},"100613120","assessement-of-effectiveness-of-seawater-nasal-sprays-on-sinonasal-symptoms-100613120","NCT07262450","Assessement of Effectiveness of Seawater Nasal Sprays on Sinonasal Symptoms","Real-word Study to Assess Effectiveness of Seawater Nasal Sprays on Sinonasal Symptoms","SeaBridge","Inclusion criteria:\n\n* Subject's age and medical condition in compliance with the intended use and population\n* Subjects who, from the investigator's judgement, should benefit from nasal wash in accordance with routine medical practice\n* Subjects with at least two nasal symptoms of intensity ≥ 3 (6 modalities intensity SNOT-22 rating-scale) among the following:\n\n  * Nasal blockage\u002Fnasal congestion\u002F stuffy nose;\n  * Runny nose;\n  * Need to blow\u002Fclear the nose;\n  * Sneezing;\n  * Thick nasal discharge\u002Fsecretions;\n  * Decreased sense of smell \u002Ftaste (replaced by \"noisy breathing\u002Fmouth breathing\" for infants)\n* Subjects with impaired nasal breathing (score ≥ 3, 6-modalities intensity rating-scale), induced by the presence of nasal symptoms\n* For acute indications (only): subjects with symptoms started not later than 72 hours prior to enrolment (Day 0).\n* For allergic rhinitis indication: perennial allergic rhinitis with and without seasonal allergic rhinitis\n* For post-surgery indication: septoplasty and rhinoseptoplasty.\n* Subject\u002Fparent willing to perform nasal wash following advices received from HCPs.\n* Subjects (or parents for babies and children) agreeing to follow the study requirements during the whole study period (up to 3 months).\n* Subject (or parent for baby and children) able to understand verbal and written local language and in capacity to fill-in questionnaire by himself.\n* Subject having daily access to internet to answer online questionnaire.\n* Subject or Parent\u002Flegal guardian of the subject has given freely and expressly her\u002Fhis informed consent.\n* Subject affiliated to the health social security system or beneficiary of an equivalent system\n\nNon-inclusion criteria:\n\n* Subject with contraindications according to each IFU.\n* Hypersensitivity or known allergy to any component of the investigational products.\n* Subject taking part in another clinical study or being in the exclusion period of another clinical study.\n* Subject already using nasal wash to manage his nasal symptoms.\n* Subject already included once in the study.\n* Subject with a member of his household already included in the study if still in the follow-up phase.\n* Subject deprived of liberty by administrative or judicial decision or under legal guardianship.","15 Days",{"count":475,"type":22},1065,[102],"The purpose of this post-market clinical investigation is to assess in a real-life setting, the effectiveness, usage, tolerance, safety and satisfaction of 4 isotonic and hypertonic seawater-based CE-marked nasal sprays.\n\nThe main questions it aims to answer are:\n\n* Efficacy,\n* Safety,\n* Usage,\n* Satisfaction, in real-life usage among infants, children, adults and pregnant or breastfeeding women suffering from acute and chronic sinonasal pathologies. The 4 medical devices under investigation will be used in accordance with their intended use, target populations and medical indications.",[479,480,481,28,482,483],"URTI","Bronchiolitis","COVID - 19","Chronic Rhinosinusitis (CRS)","Post-surgery",{"date":485,"type":39},"2025-12-03",{"date":487,"type":39},"2025-08-27",{"date":489,"type":22},"2026-08",{"name":491,"class":87},"Laboratoire de la Mer",32,{"id":494,"slug":495,"hasResults":12,"nctId":496,"briefTitle":497,"officialTitle":497,"acronym":4,"eligibilityCriteria":498,"healthyVolunteers":12,"sex":17,"minAge":378,"maxAge":219,"enrollmentInfo":499,"targetDuration":4,"studyType":23,"phases":501,"briefSummary":502,"conditions":503,"keywords":504,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":508,"lastUpdatePostDateStruct":509,"startDateStruct":511,"completionDateStruct":513,"leadSponsor":515,"locationsCount":88},"100613662","evaluation-of-the-efficacy-and-safety-of-an-intensified-strategy-of-intratonsillar-immunotherapy-itit-for-allergic-rhinitis-a-multicenter-randomized-double-blind-controlled-trial-100613662","NCT07269509","Evaluation of the Efficacy and Safety of an Intensified Strategy of Intratonsillar Immunotherapy (ITIT) for Allergic Rhinitis: A Multicenter, Randomized, Double-blind, Controlled Trial","Inclusion Criteria:\n\n1. Voluntary signing of the informed consent form\n2. Commitment to abide by the research procedures and cooperate throughout the implementation of the research\n3. Diagnosis conforms to the ARIA guidelines. The basis for the diagnosis is as follows: a. Symptoms: Paroxysmal sneezing, clear nasal discharge, nasal itching, and nasal congestion occur for 2 or more times, with symptoms persisting or accumulating for more than 1 hour each day, accompanied by tearing, eye itching, and eye redness and other ocular symptoms; b. Signs: Commonly, the nasal mucosa is pale and edematous, and nasal watery secretions are present; c. Allergen testing: Positive results for dust mite allergens SPT and\u002For serum-specific IgE, or positive nasal challenge test, requiring Der p and Der f to be positive (SPT results of ++ or higher, serum sIgE ≥ 2 grades), and other allergens in the allergen test to be negative\n4. History of allergic rhinitis caused by atopic dust mite allergens\n5. Infertile women must ensure they do not become pregnant during the treatment period\n6. Age must be between 5 and 60 years old\n\nExclusion Criteria:\n\n1. Allergic to the excipients of Arrogel (aluminum hydroxide) or the rescue medication epinephrine\n2. Suffering from respiratory system diseases other than stable asthma\n3. Pulmonary dysfunction (NYHA grade II or above, or FeV1 \\\u003C 70%) or having irreversible pathological changes in the reactive organs such as emphysema or bronchiectasis\n4. Severe acute or chronic diseases (including malignant diseases), inflammation and fever\n5. Multiple sclerosis\n6. Immune system diseases (autoimmune diseases, immune diseases caused by antigen-antibody complexes, immune deficiencies, etc.)\n7. Active pulmonary tuberculosis\n8. Severe mental disorders\n9. Obvious cardiac dysfunction\n10. Patients who have received immunotherapy within the last 1 years (subcutaneous injection or sublingual administration of allergen-specific immunotherapy, etc.)\n11. Patients who used experimental drugs or participated in other clinical studies within 30 days before treatment\n12. Patients who received IgE monoclonal antibody (mAb) treatment in the past 4 months\n13. Patients taking beta-blockers\n14. Patients who have insufficient understanding of the trial\n15. Patients whose age is not between 5 years old and 65 years old\n16. Patients who are pregnant or breastfeeding during the study period, or have plans to get pregnant\n17. Patients who cannot undergo tonsil injection due to acute or chronic tonsillitis, small tonsils, previous tonsillectomy, overly sensitive pharyngeal reflex and inability to cooperate with treatment\n18. Patients with aphthous stomatitis",{"count":500,"type":22},276,[102],"This is a multicenter, randomized, double-blind, controlled trial to evaluate the efficacy and safety of an enhanced strategy of allergen-specific immunotherapy (ITIT) in the treatment of allergic rhinitis. By recording the changes in CSMS from baseline to post-treatment in the subjects and the incidence of adverse reactions after treatment, the differences in efficacy and safety between the patients who received the basic three doses and those who received booster injections were compared. Furthermore, the impact of different booster strategies on long-term efficacy was compared to optimize the injection strategy. At the same time, the influence of different administration procedures on the immune response was evaluated.",[28],[33,505,506,507],"Intratonsillar","Allergen immunotherapy","Standardized dust mite allergen extracts","2025-11-25",{"date":510,"type":39},"2025-12-08",{"date":512,"type":22},"2025-12-30",{"date":514,"type":22},"2029-02-28",{"name":516,"class":46},"Renmin Hospital of Wuhan University",{"id":518,"slug":519,"hasResults":12,"nctId":520,"briefTitle":521,"officialTitle":521,"acronym":522,"eligibilityCriteria":523,"healthyVolunteers":12,"sex":17,"minAge":428,"maxAge":524,"enrollmentInfo":525,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":527,"conditions":528,"keywords":531,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":539,"lastUpdatePostDateStruct":540,"startDateStruct":542,"completionDateStruct":544,"leadSponsor":546,"locationsCount":47},"100612718","post-market-clinical-follow-up-study-of-an-isotonic-saline-solution-to-manage-nasal-congestion-in-case-of-flu-symptoms-colds-allergic-rhinitis-and-rhinosinusitis-in-infants-and-toddlers-100612718","NCT07257224","Post-market Clinical Follow-up Study of an Isotonic Saline Solution to Manage Nasal Congestion in Case of Flu Symptoms, Colds, Allergic Rhinitis and Rhinosinusitis in Infants and Toddlers","Nasal Baby","Inclusion Criteria:\n\n* Male and female infants \u002F toddlers aged 3 to 48 months (inclusive) at the time of enrolment.\n* Subjects with flu, cold, allergic rhinitis or rhinosinusitis as reported by their legal guardian(s) and\u002For medical history.\n* Subjects presenting at least moderately bothersome nasal congestion (blocked or stuffy nose) as reported by their legal guardian(s) and\u002For medical history and confirmed by the site investigator through non-diagnostic inspection.\n* Subjects suitable for nasal hygiene treatment with the study device according to its IFU.\n* Subjects with nasal congestion symptoms that began within 48 hours prior to enrolment.\n* Subjects whose legal guardian(s) signed written informed consent on their behalf to participate in the study.\n* Subject whose legal guardian(s) are willing and able to follow the IFU and comply with all study procedures.\n\nExclusion Criteria (if any severe symptoms are seen in the subject, the guardian will be advised to seek medical evaluation by the subject's physician):\n\n* Subjects with known hypersensitivity or intolerance to seawater or any of its natural mineral components (e.g., sodium, chloride, magnesium) as reported by their legal guardian(s) and\u002For medical history.\n* Subjects showing severe symptoms such as persistent fever (\\>38°C), severe cough, ear pain, or respiratory distress, as reported by their legal guardian(s) and\u002For medical history.\n* Subjects whose legal guardian(s) and\u002For medical history report any ongoing medical diagnosis or treatment for acute infection or chronic respiratory disease (e.g., asthma, pneumonia, laryngotracheobronchitis, sinusitis, etc.).\n* Subjects whose legal guardians(s) and\u002For medical history report any type of immunodeficiency.\n* Subjects whose legal guardian(s) and\u002For medical history report a neurological condition that may affect respiratory functioning.\n* Subjects with visible nasal injury, wounds or bleeding, or any condition that may contraindicate the use of the study device according to the device IFU.\n* Subjects who are currently participating or have participated in another clinical investigation within the last 30 days prior to enrolment.\n* Subjects using saline nasal drops or nasal sprays or pumps other than the study product within 12 hours prior to the time of enrolment or during the study.\n* Subjects using the study product within 24 hours prior to the time of enrolment in the study.\n* Subject using antibiotics, antivirals, intranasal medications, decongestants, antihistamines, mucolytics, echinacea, combination cold formulas, supplements containing ≥ 10 mg zinc that could influence symptom scores within 12 hours prior to the time of enrolment or during the study.","48 Months",{"count":526,"type":22},83,"The goal of this observational post-market clinical follow-up study is to evaluate the safety and performance of the CE-marked nasal spray in the management of nasal congestion in case of flu, colds, allergic rhinitis and rhinosinusitis in infants and toddlers aged 3 to 48 months at day 5 post-enrolment. Enrolment does not require establishing a medical diagnosis; eligibility is based on guardian-reported nasal congestion consistent with lay use of the device.\n\nParticipants will be:\n\n* Evaluated by a healthcare professional for eligibility.\n* Receive treatment with the CE-marked nasal spray according to its Instructions for Use, for up to 14 days.\n* Have their legal guardians report symptom severity and improvement using standardized scales (Visual Analog Scale) during follow-up visits on Day 2, Day 5, and Day 14 and device usability on Day 14.\n\nThis study does not include a comparison group and reflects real-world use of the device in routine pediatric care.",[529,63,28,65,530],"Nasal Congestion","Flu Symptom",[532,533,534,535,536,537,538],"infants","toddlers","Upper Respiratory Tract Infections","Pediatric nasal spray","nasal spray","Seawater isotonic solution","Post-market clinical follow-up (PMCF)","2025-11-20",{"date":541,"type":39},"2025-12-02",{"date":543,"type":22},"2025-12",{"date":545,"type":22},"2026-11",{"name":547,"class":87},"Laboratoires Quinton International S.L.",{"id":549,"slug":550,"hasResults":12,"nctId":551,"briefTitle":552,"officialTitle":553,"acronym":554,"eligibilityCriteria":555,"healthyVolunteers":12,"sex":17,"minAge":97,"maxAge":4,"enrollmentInfo":556,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":558,"conditions":559,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":562,"lastUpdatePostDateStruct":563,"startDateStruct":565,"completionDateStruct":567,"leadSponsor":569,"locationsCount":571},"100560673","performance-and-safety-assessment-of-the-mechanical-decongestant-seawater-spray-enriched-with-essential-oils-from-laboratoires-gilbert-in-patient-with-acute-rhinitis-associated-with-nasal-obstruction-100560673","NCT06580210","Performance and Safety Assessment of the Mechanical Decongestant Seawater Spray Enriched With Essential Oils From Laboratoires Gilbert in Patient With Acute Rhinitis Associated With Nasal Obstruction","Prospective Multicenter Clinical Investigation to Evaluate the Performance and the Safety of the Mechanical Decongestant Seawater Spray Enriched With Essential Oils From Laboratoires Gilbert (DEMECA)","DEMECA","Inclusion Criteria:\n\n* 1\\. Patient ≥ 12 years,\n* 2\\. Patient with acute rhinitis associated with nasal obstruction during infectious episodes such as rhynopharyngitis (cold), rhinosinusitis, or during non-infectious episodes as allergic rhinitis,\n* 3\\. a. Informed adult patient who has given written consent prior to any study specific procedure,\n* b. Informed minor patients who has given assent and whose legal guardians have given written consent prior to any study specific procedure,\n* 4\\. Patient able to meet the study requirements (questionnaire completion),\n* 5\\. Patient affiliated to a social security scheme.\n\nExclusion Criteria:\n\n* 1\\. Patient who does not want to participate to the clinical investigation,\n* 2\\. Hypersensitivity to seawater and\u002For known allergies to any of the ingredients of the spray,\n* 3\\. A child with a history of febrile convulsions,\n* 4\\. Diseases leading to respiratory insufficiency,\n* 5\\. Patient suffering from nasal deformity or nasal polyps leading to chronic nasal obstruction,\n* 6\\. Patient on local ans systemic vasoconstrictors, local and systemic corticosteroids and antihistamines, non-steroidal anti-inflammatory (NSAIDs), antibiotics and local antiseptics,\n* 7\\. Concomitant use of other nasal sprays, essential oils for local nasal use and nsal cream or gel,\n* 8\\. Patient under guardianship, curatorship of safeguard of justice.",{"count":557,"type":22},114,"The purpose of this post-market clinical investigation is to assess the performance and the safety of the mechanical decongestant seawater spray enriched with essential oils from Laboratoires Gilbert. The study will evaluate the results of the spray on the acute rhinitis with nasal obstruction over a 7 days period.",[560,62,65,561,28],"Acute Rhinitis","Rhinopharyngitis","2025-11-18",{"date":564,"type":39},"2025-11-21",{"date":566,"type":39},"2024-10-22",{"date":568,"type":22},"2026-06-07",{"name":570,"class":87},"Laboratoires Gilbert",3,{"id":573,"slug":574,"hasResults":12,"nctId":575,"briefTitle":576,"officialTitle":577,"acronym":578,"eligibilityCriteria":579,"healthyVolunteers":12,"sex":17,"minAge":97,"maxAge":4,"enrollmentInfo":580,"targetDuration":4,"studyType":23,"phases":582,"briefSummary":583,"conditions":584,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":585,"lastUpdatePostDateStruct":586,"startDateStruct":588,"completionDateStruct":590,"leadSponsor":592,"locationsCount":370},"100477237","safety-and-performance-assessment-of-the-decongestant-seawater-spray-pocket-valve-enriched-with-essential-oils-in-patients-with-acute-rhinitis-associated-with-nasal-obstruction-devalpo-100477237","NCT05494346","Safety and Performance Assessment of the Decongestant Seawater Spray Pocket Valve Enriched With Essential Oils in Patients With Acute Rhinitis Associated With Nasal Obstruction: \"DEVALPO\"","Prospective Multicenter Clinical Investigation Evaluating the Performance and Safety of Gilbert Laboratories' Decongestant Seawater Spray Pocket Valve Enriched With Essential Oils","DEVALPO","Inclusion Criteria:\n\n* 1\\. Patient ≥ 12 years.\n* 2\\. Patient with acute rhinitis associated with nasal obstruction during infectious episodes such as rhinopharyngitis (cold), rhinosinusitis, or during non-infectious episodes such as allergic rhinitis.\n* 3\\. a. Informed adult patient who has given written consent prior to any study specific procedure. b. Informed minor patient who has given assent and whose legal guardians have given written consent prior to any study-specific procedure.\n* 4\\. Patient able to meet the study requirements for monitoring, spray use, and questionnaire completion.\n* 5\\. Patient affiliated to a social security scheme.\n\nExclusion Criteria:\n\n* 1\\. Pregnant and\u002For breastfeeding woman\n* 2\\. Hypersensitivity to seawater and\u002For known allergies to any of the ingredients of the spray.\n* 3\\. Diseases causing narrowing of the airways (e.g. asthma, chronic obstructive pulmonary disease (COPD)) and\u002For respiratory insufficiency.\n* 4\\. Patients with uncontrolled asthma (GINA score greater than or equal to 4)\n* 5\\. Patients undergoing allergy desensitization\n* 6\\. Patients suffering from chronic nasal obstruction due to a deformation of the nasal wall or nasal polyps. creams or gels.\n* 7\\. Patients taking local and systemic vasoconstrictors, corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), antibiotics, and local antiseptics.\n* 8\\. Concomitant use of other nasal sprays, essential oils for local nasal use, creams, or gels for the nose.\n* 9\\. Patients under guardianship, conservatorship, or legal protection.",{"count":581,"type":22},101,[102],"The purpose of this pre-market clinical investigation is to assess the safety and the performance of decongestant seawater spray pocket valve enriched with essential oils by Gilbert Laboratories. The study will evaluate the results of acute rhinitis associated with nasal obstruction using the decongestant seawaterspray pocket valve enriched with essential oils over a 8 day period.",[560,62,65,561,28],"2025-09-19",{"date":587,"type":39},"2025-09-25",{"date":589,"type":39},"2023-06-23",{"date":591,"type":22},"2026-06-30",{"name":570,"class":87},{"id":594,"slug":595,"hasResults":12,"nctId":596,"briefTitle":597,"officialTitle":598,"acronym":4,"eligibilityCriteria":599,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":219,"enrollmentInfo":600,"targetDuration":4,"studyType":23,"phases":601,"briefSummary":602,"conditions":603,"keywords":605,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":624,"lastUpdatePostDateStruct":625,"startDateStruct":627,"completionDateStruct":629,"leadSponsor":631,"locationsCount":88},"100601810","effect-of-combined-probiotics-and-vitamin-d-on-symptoms-of-allergic-rhinitis-100601810","NCT07115342","Effect of Combined Probiotics and Vitamin D on Symptoms of Allergic Rhinitis","Investigating Efficacy of Combined Probiotics and Vitamin D Supplementation in Reducing Symptoms and Improving Quality of Life in Patients With Allergic Rhinitis","Inclusion Criteria:\n\nConfirmed diagnosis of AR based on clinical history and specific IgE testing or will be screened for eligibility by the modified Mini Rhino-conjunctivitis Quality of Life Questionnaire (Mini RQLQ).\n\nPersistent rhinitis symptoms for at least two consecutive years.\n\nPresence of two or more AR symptom domains, including sneezing, watery rhinorrhea, nasal itching, and nasal congestion, with symptoms persisting or accumulating for more than 1 hour daily with \\> 2 scores without taking medication.\n\nSymptoms may be accompanied by ocular manifestations such as eye itching, tearing, and redness\n\nVoluntarily and in writing, sign an informed consent form agreeing to participate in this study and able to complete the study as required by the trial protocol.\n\nVitamin D insufficiency or deficiency. Deficiency: \\\u003C 20 ng\u002FmL (\\\u003C 50 nmol\u002FL), Insufficiency: 20-29 ng\u002FmL (50-75 nmol\u002FL)\n\nExclusion Criteria:\n\nUse of systemic corticosteroids, immunosuppressive therapy, or medications affecting the gut microbiota (antimicrobials, probiotics, prebiotics, intestinal mucosal protective agents, etc.) within 4 weeks prior to screening.\n\nRegular use of probiotics, prebiotics, or vitamin D supplements within 6 months prior to screening.\n\nHistory of or concurrent use of medications or supplements that alter serum 25(OH)D levels, such as barbiturates, bisphosphonates, sulfasalazine, anticonvulsants, antiretrovirals, omega-3 supplements, or ketoconazole.\n\nDiagnosed with pulmonary tuberculosis, allergic asthma, chronic obstructive pulmonary disease (COPD), mast cell activation syndrome, or other respiratory diseases requiring treatment.\n\nCoexisting conditions such as nasal polyps, severe nasal septum deviation, severe gastrointestinal diseases (e.g., severe diarrhea or inflammatory bowel diseases), metabolic syndrome (e.g., obesity, dyslipidemia, hypertension, diabetes), or chronic systemic diseases or malignancies.\n\nHistory of autoimmune diseases or chronic inflammatory conditions.\n\nSinusitis, otitis media, or respiratory tract infections or upper respiratory infections within 14 days of the study start.\n\nKnown hypersensitivity or allergy to any component of the probiotics or other study interventions.\n\nPhysical signs or symptoms suggestive of renal, hepatic, or cardiovascular disease.\n\nPregnant or lactating women.",{"count":166,"type":22},[102],"The goal of this clinical trial is to learn if taking probiotics, vitamin D, or both together can help lower symptoms of allergic rhinitis (AR) and improve quality of life in adults. Allergic rhinitis is a condition that causes sneezing, nasal congestion, and itchy or watery eyes.\n\nThe main questions this study aims to answer are:\n\n• Do these supplements improve the quality of life for people with AR?\n\nResearchers will compare four groups:\n\n* People taking probiotics and vitamin D\n* People receiving standard treatment only (control group)\n\nParticipants will:\n\n* Take a probiotic capsule daily and\u002For a vitamin D tablet (based on blood levels) for 12 weeks\n* Continue standard allergic rhinitis treatment (like antihistamines or nasal sprays)\n* Visit the clinic for checkups and lab tests\n* Complete surveys about their symptoms and quality of life\n\nThis study will help researchers understand if adding probiotics and\u002For vitamin D to standard care can help people with allergic rhinitis feel better.",[28,604],"Allergic Rhinitis (AR)",[606,607,608,609,610,611,612,613,614,615,616,617,618,619,620,621,622,623,28],"Nutritional Supplementation","Integrative Medicine","Vitamin D Deficiency","T Regulatory Cells","Th2 Inflammation","Immune Response","Anti-inflammatory","Lactobacillus","Bifidobacterium","Gut Microbiota","Complementary Therapy","Combined Supplementation","Clinical Trial","Quality of Life","Nasal Symptoms","Immunomodulation","Vitamin D","Probiotics","2025-08-10",{"date":626,"type":39},"2025-08-14",{"date":628,"type":39},"2025-08-01",{"date":630,"type":22},"2025-11-30",{"name":632,"class":46},"Tanta University",{"id":634,"slug":635,"hasResults":12,"nctId":636,"briefTitle":637,"officialTitle":638,"acronym":4,"eligibilityCriteria":639,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":219,"enrollmentInfo":640,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":641,"conditions":642,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":643,"lastUpdatePostDateStruct":644,"startDateStruct":646,"completionDateStruct":648,"leadSponsor":650,"locationsCount":88},"100601424","impact-of-pet-cats-on-nasal-and-gut-microbiota-in-patients-with-cat-allergen-allergy-100601424","NCT07110311","Impact of Pet Cats on Nasal and Gut Microbiota in Patients With Cat Allergen Allergy","Effects of Pet Cats on Nasal and Intestinal Microorganisms in Patients With Allergic Rhinitis Who Are Allergic to Cat Allergen","Inclusion Criteria:\n\n* Adult patients (18-65 years).\n* Patients with moderate to severe dust mite allergic rhinitis were diagnosed based on clinical history and positive cat allergen sensitization tests (skin prick test and\u002For specific IgE).\n* Patients who visited the Department of Otolaryngology of the First Affiliated Hospital of Nanjing Medical University.\n\nExclusion Criteria:\n\n* Patients who refused to accept specimen and questionnaire collection.\n* Patients who had nasal diseases other than allergic rhinitis, such as nasal papilloma and nasal malignant tumor.",{"count":296,"type":22},"It has been reported that the incidence of allergic rhinitis (AR) is as high as 24.1% in adults and 16.8% in children in China. A study explored the changes in the incidence of AR in China, and the study showed that the incidence of AR in many cities in China increased significantly from 2005 to 2011. The latest Chinese guidelines for the diagnosis and treatment of allergic rhinitis pointed out that AR is an independent risk factor for asthma, and 40% of AR patients can be complicated with asthma. CARRAD reported that in adult asthma patients who received skin prick test or serum specific IgE (sIgE) for allergens, The positive rates of at least one allergen were 65.4% and 75.4%, respectively. With the acceleration of urbanization and the improvement of people's economic level, more and more families keep pets. Pets can promote people's physical and mental health, but there are also more and more people who are allergic to pets. Some studies have shown that pets are the third major allergen of respiratory allergic diseases, next to dust mites and pollen. Cats are by far one of the most popular pets, but in recent years, the prevalence of cat allergen has gradually increased. Animal allergens are present in saliva, urine, and dander, and they spread into the environment by adhering to the hair and dander of the animals, such that even in homes without pets, the level of allergens in the environment is sufficient to sensitize people. However, at present, the microbial impact of the microorganisms carried by pet cats on their owners and the living environment is unknown.",[28],"2025-07-31",{"date":645,"type":39},"2025-08-07",{"date":647,"type":39},"2024-11-14",{"date":649,"type":22},"2032-11-01",{"name":651,"class":46},"The First Affiliated Hospital with Nanjing Medical University",{"id":653,"slug":654,"hasResults":12,"nctId":655,"briefTitle":656,"officialTitle":656,"acronym":4,"eligibilityCriteria":657,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":658,"enrollmentInfo":659,"targetDuration":4,"studyType":23,"phases":661,"briefSummary":662,"conditions":663,"keywords":664,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":666,"lastUpdatePostDateStruct":667,"startDateStruct":669,"completionDateStruct":671,"leadSponsor":673,"locationsCount":88},"100599073","study-of-the-effects-and-mechanisms-of-yeast-postbiotics-on-persistent-allergic-rhinitis-symptoms-100599073","NCT07079748","Study of the Effects and Mechanisms of Yeast Postbiotics on Persistent Allergic Rhinitis Symptoms","Inclusion Criteria:\n\n1. Aged between 18 and 35 years;\n2. Meeting the symptom criteria for persistent allergic rhinitis (AR) as defined in the Chinese Guidelines for Diagnosis and Treatment of Allergic Rhinitis (2022, Revised Edition): (1) Symptoms: Two or more of the following-paroxysmal sneezing, watery rhinorrhea, nasal itching, and nasal congestion-lasting continuously or cumulatively for at least 1 hour per day; ocular symptoms such as tearing, itching, and redness may also be present; (2) Persistent AR: Symptoms occur on ≥4 days per week and persist for ≥4 consecutive weeks;\n3. No use of probiotics, prebiotics, synbiotics, antihistamines, corticosteroids, or immunosuppressants within 1 month prior to screening;\n4. Willing and able to maintain usual physical activity levels and dietary patterns during the study;\n5. Able and willing to sign the informed consent form voluntarily.\n\nExclusion Criteria:\n\n1. Use of antibiotics, osmotic laxatives (e.g., magnesium sulfate, lactulose), anthraquinone-containing agents (e.g., rhubarb, aloe, senna), or gastrointestinal motility-promoting drugs (e.g., metoclopramide, domperidone, cisapride) within 1 month prior to screening;\n2. Diagnosed with non-allergic rhinitis (e.g., vasomotor rhinitis, infectious rhinitis, hormonal rhinitis, drug-induced rhinitis), or with nasal polyps, severe nasal septum deviation, cerebrospinal fluid rhinorrhea, or aspirin-exacerbated respiratory disease (AERD);\n3. Patients with uncontrolled allergic comorbidities, including sinusitis, otitis media, allergic asthma, or atopic dermatitis;\n4. History of serious gastrointestinal diseases (e.g., severe diarrhea, inflammatory bowel disease), or gastrointestinal endoscopy within the past month;\n5. Diagnosed with congenital genetic disorders, primary immunodeficiency diseases, severe systemic illnesses, or malignancies;\n6. Pregnant or lactating women, or women with plans to conceive during the study period.","35 Years",{"count":660,"type":22},80,[102],"This study is designed as a randomized, double-blind, placebo-controlled human intervention trial among university students with persistent allergic rhinitis (AR) symptoms. The aim is to evaluate the effectiveness of yeast postbiotics in alleviating persistent AR symptoms and to explore the potential mechanisms by which yeast postbiotics modulate the gut microbiota to improve AR-related outcomes. A stratified randomization method will be applied to assign participants into the yeast postbiotic group and the placebo group. Stratification will be based on(1) Sex (male\u002Ffemale), and (2) Physician-diagnosed AR status (yes\u002Fno, based on self-reported clinical history), ensuring comparability between the two groups. During the intervention period, participants in the yeast postbiotic group will take two capsules of yeast postbiotic supplements daily after meals, while the placebo group will take two placebo capsules, identical in appearance and composition except without the active ingredients. The total study duration is 15 weeks, including a 1-week run-in period, 12-week intervention, and 2-week follow-up after the intervention.\n\nAll participants will be asked to complete a daily nasal symptom score (TNSS) and report any adverse events. At week 0, week 4, and week 12, follow-up assessments will be conducted, including: symptom and quality-of-life questionnaires (e.g., VAS, RQLQ), dietary intake surveys, anthropometric measurements (height, weight, body fat percentage), and biological sample collection (including blood, urine, saliva, and feces). Additionally, saliva samples will be collected specifically at week 2 of the intervention to assess mucosal immune markers.",[28],[28,665],"Yeast Postbiotics","2025-07-18",{"date":668,"type":39},"2025-07-23",{"date":670,"type":22},"2025-07-25",{"date":672,"type":22},"2026-12-31",{"name":674,"class":46},"LanZhou University",{"id":676,"slug":677,"hasResults":12,"nctId":678,"briefTitle":679,"officialTitle":679,"acronym":680,"eligibilityCriteria":681,"healthyVolunteers":96,"sex":17,"minAge":351,"maxAge":4,"enrollmentInfo":682,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":684,"conditions":685,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":687,"lastUpdatePostDateStruct":688,"startDateStruct":690,"completionDateStruct":691,"leadSponsor":693,"locationsCount":88},"100551371","factors-determining-tolerance-to-nasal-allergen-exposure-with-advanced-age-in-a-subset-of-birch-pollen-allergic-subjects-100551371","NCT06459219","Factors Determining Tolerance to Nasal Allergen Exposure With Advanced Age in a Subset of Birch Pollen Allergic Subjects","AllergyAge","Inclusion Criteria:\n\n* General inclusion criteria Age ≥ 60 years Willingness to participate in the study and to follow the protocol Written informed consent Standard healthcare insurance Subjects should be available during the entire study period\n* Patient group specific inclusion criteria (n=38 per group):\n\n  1. Group 1 (current allergy):\n\n     Ongoing intermittent allergic rhinoconjunctivitis to birch pollen with moderate to severe symptoms according to ARIA guidelines for at least 10 years Positive Skin prick test (SPT) to birch pollen and\u002For Bet v 1-specific IgE ≥0.35kUA\u002FL as measured by ImmunoCAP\n  2. Group 2 (former allergy):\n\n     History of intermittent allergic rhinoconjunctivitis to birch pollen ongoing with moderate to severe symptoms according ARIA guidelines for at least ten years (verified by at least one medical record including SPT results), but no symptoms for at least the three past consecutive seasons Positive or negative SPT to birch pollen and Bet v 1-specific IgE ≤ or ≥0.35kUA\u002FL as measured by ImmunoCAP\n  3. Group 3 (never allergy):\n\nNo history of and no ongoing allergic rhinoconjunctivitis to birch pollen Negative SPT to birch pollen and Bet v 1-specific IgE ≤ 0.35kUA\u002F\n\nExclusion Criteria:\n\n* \\- Evidence of acute, chronic, malignant or general diseases-assessed by asking the patient\n* A History of anaphylaxis\n* Utilization of leukotriene modifiers or long-acting antihistamines\n* Chronic or intermittent use of oral, inhaled, intramuscular or intravenous corticosteroids\n* Nasal polyps, history of chronic sinusitis or considerable deviation of the nasal septum\n* Rhinitis secondary to other causes\n* Contra-indications to skin prick testing, for example, skin irritation in the test area and urticaria facticia\n* Cardiovascular diseases requiring treatment with anti-hypertensive medication or beta-blockers\n* Known clotting disorders\n* Chronic use of additional medications that would affect assessment and the results of the study (e.g., tricyclic antidepressants that block both H1 and H2 receptors)\n* Pregnant or breastfeeding females\n* Actual disability that would influence subject's ability to participate in the study\n* History of mental illness, intellectual deficiency, drug or alcohol abuse\n* Active asthma requiring treatment\n* Allergen immunotherapy within the last 5 years to any allergen\n* Current and former smokers who stopped smoking \\\u003C1 year ago",{"count":683,"type":22},152,"Nasal allergen study in patients aged 60+ with or without current respiratory allergy",[28,686],"Allergic Conjunctivitis","2025-05-06",{"date":689,"type":39},"2025-05-07",{"date":122,"type":22},{"date":692,"type":22},"2028-10-01",{"name":694,"class":46},"Sven Schneider, MD",{"id":696,"slug":697,"hasResults":12,"nctId":698,"briefTitle":699,"officialTitle":700,"acronym":4,"eligibilityCriteria":701,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":219,"enrollmentInfo":702,"targetDuration":4,"studyType":23,"phases":704,"briefSummary":705,"conditions":706,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":707,"lastUpdatePostDateStruct":708,"startDateStruct":709,"completionDateStruct":711,"leadSponsor":713,"locationsCount":47},"100551617","efficacy-and-safety-of-arbidol-in-the-treatment-of-allergic-rhinitis-100551617","NCT06462417","Efficacy and Safety of Arbidol in the Treatment of Allergic Rhinitis","Study on the Efficacy and Safety of Oral Administration of Arbidol in the Treatment of Allergic Rhinitis Patients","Inclusion Criteria:\n\n* 1\\. Patients with allergic rhinitis (in line with the diagnostic criteria of the \"Guidelines for the Diagnosis and Treatment of Allergic Rhinitis (2015, Tianjin)\" formulated by the Rhinology Group of the Otolaryngology-Head and Neck Surgery Branch of the Chinese Medical Association).\n* 2\\. At least 2 nasal symptoms are moderate or above (referring to sneezing, runny nose, nasal itching, nasal congestion with at least 2 symptoms ≥2 points).\n* 3\\. Female subjects are not pregnant or lactating and have no pregnancy and lactation plans during the trial medication period.\n* 4\\. The subject has not participated in other clinical trials in the previous three months and agrees not to participate in other clinical trials before reaching the endpoint of this trial.\n* 5\\. The subject\u002Flegally authorized representative understands the purpose and procedures of the trial and voluntarily signs the informed consent form, voluntarily participates in the study and complies with the study regulations, understands and complies with the medication dosage and follow-up plan, and correctly records the scale score, the number of medications, concomitant medication and adverse event records.\n\nExclusion Criteria:\n\n* 1\\. Who are allergic to Arbidol.\n* 2\\. Patients with abnormal liver and kidney function (ALT and AST exceed the maximum limit of normal value by 1.5 times, and Cr exceeds the upper limit of normal value).\n* 3\\. Patients with abnormal ECG parameters and clinically significant (PR\\>220ms, QRS\\>120ms, QTc\\>450ms) and bradycardia.\n* 4\\. Patients with severe asthma or acute asthma exacerbations.\n* 5\\. Patients with structural heart disease, severe hypertension (blood pressure greater than 180\u002F110mmHg), diabetes, hyperthyroidism, malignant tumors, immunocompromise, and mental illness. Patients with structural heart disease, severe hypertension (blood pressure greater than 180\u002F110mmHg), diabetes, hyperthyroidism, malignant tumors, immunocompromise, and mental illness.\n* 6\\. Patients with nasal polyps, severe deviated nasal septum, sinusitis, and hypertrophic rhinitis.\n* 7\\. Who have participated in other clinical studies within 3 months.\n* 8\\. Women are pregnant or lactating, in childbearing age with positive blood pregnancy test, or have pregnancy and lactation plans during the trial medication.\n* 9\\. Drug abuse and alcoholism.\n* 10\\. Who have received allergen-specific immunotherapy within 3 years.\n* 11\\. Positive infectious disease screening (hepatitis B surface antigen, hepatitis C antibody, AIDS antibody and treponema pallidum antibody).\n* 12\\. Who should not be included if there are other reasons in the opinion of the investigator.",{"count":703,"type":22},15,[102],"The most important treatment for AR is topical nasal medications (including nasal corticosteroids, nasal antihistamines, nasal decongestants, and nasal saline irrigation etc.), which are still limited. Arbidol may inhibit molecular targets involved in the pathogenesis of AR. This study intends to explore the effect of Arbidol in the treatment of allergic rhinitis and evaluate its efficacy and safety.",[28],"2025-05-03",{"date":689,"type":39},{"date":710,"type":39},"2024-07-11",{"date":712,"type":22},"2025-06-30",{"name":714,"class":46},"Zheng Liu"]